MBL is committed to being a leading manufacturer & supplier of diagnostic reagents that facilitate further advances in personalized medicine & individualization of medical care
MBL Obtains Regulatory Approval for SARS-CoV-2 and Influenza Virus Antigen Test OTC Kit
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
MBL Launches an OTC Kit for SARS-CoV-2 Antigen Test
Medical & Biological Laboratories Co., Ltd. successfully acquired regulatory approval on November 11, 2022 for its SARS-CoV-2 antigen test OTC kit “GLINE-2019-nCoV Agキット（一般用).”
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.
MBL Obtained European Quality Management System Certificate (IVDR)
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
MEBGEN BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma
MBL announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare for production ...